Key result
In an atherosclerotic rabbit model, rupture-prone plaques had a higher vessel wall relaxation rate on gadofosveset MRI compared with stable plaques (2.30 vs 1.86 s-1; P<0.001).
Why the study?
Does magnetic resonance imaging using the albumin-binding contrast agent gadofosveset identify rupture-prone atherosclerotic plaques by measuring vascular permeability in an atherosclerotic rabbit model?
Does magnetic resonance imaging using the albumin-binding contrast agent gadofosveset identify rupture-prone atherosclerotic plaques by measuring vascular permeability in an atherosclerotic rabbit model?
Absolute Event Rate: 2.3% vs 1.86%
p-value: p=<0.001
T1 mapping with the albumin-binding contrast agent gadofosveset can quantify increased vascular permeability to identify rupture-prone atherosclerotic plaques in a preclinical model.
May inform permeability-based plaque imaging development; leaves open human validation.
Background— Compromised structural integrity of the endothelium and higher microvessel density increase vascular permeability. We investigated whether vascular permeability measured in vivo by magnetic resonance imaging using the albumin-binding contrast agent, gadofosveset, is a surrogate marker of rupture-prone atherosclerotic plaque in a rabbit model. Methods and Results— New Zealand white rabbits (n=10) were rendered atherosclerotic by cholesterol-diet and endothelial denudation. Plaque rupture was triggered with Russell’s viper venom and histamine. Animals were imaged pre-triggering, at 3 and 12 weeks, to quantify plaque area, vascular permeability, vasodilation, and stiffness and post-triggering to identify thrombus. Plaques identified on the pretrigger scans were classified as stable or rupture-prone based on the absence or presence of thrombus on the corresponding post-trigger magnetic resonance imaging, respectively. All rabbits had developed atherosclerosis, and 60% had ruptured plaques. Rupture-prone plaques had higher vessel wall relaxation rate (R 1 ; 2.30±0.5 versus 1.86±0.3 s −1 ; P <0.001), measured 30 minutes after gadofosveset administration, and higher R 1 /plaque area ratio (0.70±0.06 versus 0.47±0.02, P = 0.01) compared with stable plaque at 12 weeks. Rupture-prone plaques had higher percent change in R 1 between the 3 and 12 weeks compared with stable plaque (50.80±7.2% versus 14.22±2.2%; P <0.001). Immunohistochemistry revealed increased vessel wall albumin and microvessel density in diseased aortas and especially in ruptured plaque. Electron microscopy showed lack of structural integrity in both luminal and microvascular endothelium in diseased vessels. Functionally, the intrinsic vasodilation of the vessel wall decreased at 12 weeks compared with 3 weeks (18.60±1.0% versus 23.43±0.8%; P <0.001) and in rupture-prone compared with stable lesions (16.40±2.0% versus 21.63±1.2%; P <0.001). Arterial stiffness increased at 12 weeks compared with 3 weeks (5.00±0.1 versus 2.53±0.2 m/s; P <0.001) both in animals with stable and rupture-prone lesions. Conclusions— T1 mapping using an albumin-binding contrast agent (gadofosveset) could quantify the changes in vascular permeability associated with atherosclerosis progression and rupture-prone plaques.
No takes yet. Share an insight, caveat, or question.
Phinikaridou et al. (2016) studied Atherosclerosis (n=10). Rupture-prone atherosclerotic plaque vs. Stable plaque was evaluated on Vessel wall relaxation rate (R1) measured 30 minutes after gadofosveset administration at 12 weeks (p=<0.001). In an atherosclerotic rabbit model, rupture-prone plaques had a higher vessel wall relaxation rate on gadofosveset MRI compared with stable plaques (2.30 vs 1.86 s-1; P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: